Oncotarget

Research Papers:

Down-regulation of SOSTDC1 promotes thyroid cancer cell proliferation via regulating cyclin A2 and cyclin E2

Weiwei Liang, Hongyu Guan, Xiaoying He, Weijian Ke, Lijuan Xu, Liehua Liu, Haipeng Xiao and Yanbing Li _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:31780-31791. https://doi.org/10.18632/oncotarget.5566

Metrics: PDF 1301 views  |   HTML 1514 views  |   ?  


Abstract

Weiwei Liang1,*, Hongyu Guan1,*, Xiaoying He1, Weijian Ke1, Lijuan Xu1, Liehua Liu1, Haipeng Xiao1 and Yanbing Li1

1 Department of Endocrinology and Diabetes Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China

* These authors have contributed equally to this work

Correspondence to:

Yanbing Li, email:

Keywords: SOSTDC1, thyroid cancer, proliferation, cyclin A2, cyclin E2

Received: February 26, 2015 Accepted: August 13, 2015 Published: September 10, 2015

Abstract

Sclerostin domain containing protein 1 (SOSTDC1) is down-regulated and acts as a tumor suppressor in some kinds of cancers. However, the expression pattern and biological significance of SOSTDC1 in thyroid cancer are largely unknown. We demonstrated that SOSTDC1 was significantly down-regulated in thyroid cancer. Ectopic over-expression of SOSTDC1 inhibited proliferation and induced G1/S arrest in thyroid cancer cells. Moreover, SOSTDC1 over-expression suppressed the growth of tumor xenografts in nude mice. We also found that elevated SOSTDC1 led to inhibition of cyclin A2 and cyclin E2. Together,our results demonstrate that SOSTDC1 is down-regulated in thyroid cancer and might be a potential therapeutic target in the treatment of thyroid cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 5566